There are many promising studies for TNBC. Please visit www.clinicaltrials.gov for open studies. Below are some that I have found to be interesting.
TRIALS FOR PATIENTS WITH STAGE IV TNBC:
Dr. Vince Cryns and Dr. Ruth O'Regan at The Philadelphia Company of Oncoceutics have developed a new drug called ONC201. The clinical trial testing the drug efficacy in combination with a low methionine diet.
Pembrolizumab (MK-3475) is a form of immunotherapy that blocks the PD-1 pathway. Some cancers take control of the PD-1 pathway, which helps them to hide from T cells (immune cells) made by your body. The Keynote trials are listed on ClinicalTrials.gov as well as the Merck site. Please direct your provider to keynoteclinicaltrials.com/researchers to help find the right trial for you.
Another very important trial is examining the safety and efficacy of GTx-024, a SARM (selective androgen receptor modulator) in stage IV patients with TNBC. SARMs much like SERMs (selective estrogen receptor modulators- e.g. Tamoxifen) may target TNBC cells, even those with weak androgen receptor expression. So far, the most common reported side-effects are headache and back pain. The phase II trial is being conducted by Drs. Yuan (Ca), Brufsky (Pa), and Linden (Wa). Please see the ClinicalTrials.gov.
TRIALS FOR PATIENTS WITH NON-METASTATIC TNBC:
The Randomized Controlled Trial of Genomically Directed Therapy in Triple Negative Breast Cancer sounds very interesting and could be an excellent opportunity. This is cutting edge and way over due! Here's the link from the website of NCI!
Another intriguing study is Personalized DNA Vaccine in Treating Patients with Triple-Negative Breast Cancer Following Chemotherapy at ClinicalTrials.gov.
The Penn-SURMOUNT trial at the Abramson Cancer Center will assess the bone marrow of women who have already been treated for breast cancer for the presence of dormant tumor cells (DTCs) and offer women trial opportunities if present. The I-SPY 2 TRIAL and the ISPY-SURMOUNT study is looking at bone marrow and blood samples in women receiving neo-adjuvant chemotherapy. See details at link above.
DTCs have been shown to be a potentially useful predictive tool for tumor relapse (usually distant metastases). Results, however, are mixed. Please see my separate blog on this topic.
Keynote breast cancer trials are also enrolling patients with locally advanced TNBC. Please see the link above.
Dr. Moulder at MD Anderson is conducting a phase II trial using Mirvetuximab Soravtansine in patients with localized folate receptor alpha-positive TNBC predicted to be insensitive to chemotherapy. Phone: 713-563-0730 or write CR_Study_Registration@mdanderson.org.
Be on the look-out for clinical trials of a molecule that targets TNBC cells!
Adeboye Adejare, PhD, (Professor of Pharmaceutical Sciences) and Isabelle Mercier, PhD, (Associate Professor of Pharmaceutical Science) from the University of the Sciences in collaboration with Zeynep Ates-Alagoz, PhD, who is a professor of pharmaceutical chemistry at Ankara University (Turkey), have discovered a small molecule that exhibits selectivity kills TNBC cells while sparing normal surrounding cells! Please see the website for USciences.
Brian Kirschner Director of Communications215email@example.com
Jenna Pizzi Communications Manager215firstname.lastname@example.org